AbbVie: Rinvoq Meets Key Endpoints in Phase 3 Crohn's Disease Study
December 06 2021 - 9:20AM
Dow Jones News
By Colin Kellaher
AbbVie Inc. on Monday said its Rinvoq immunology drug met the
key endpoints in a Phase 3 induction study in patients with the
inflammatory bowel disorder Crohn's disease.
The North Chicago, Ill., biopharmaceutical company said Rinvoq
achieved both primary endpoints of clinical remission and
endoscopic response at week 12 in the study, which enrolled
patients with moderate to severe Crohn's disease who had an
inadequate response or were intolerant to biologic therapy.
AbbVie said the trial is the first of a pair of Phase 3
induction studies to evaluate the safety and efficacy of Rinvoq in
adults with moderate to severe Crohn's disease. AbbVie is studying
the JAK inhibitor in several other immune-mediated inflammatory
diseases.
Rinvoq is approved in the U.S. for adults with moderately to
severely active rheumatoid arthritis and in Europe in indications
in atopic dermatitis, active rheumatoid arthritis, active psoriatic
arthritis and active ankylosing spondylitis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 06, 2021 09:05 ET (14:05 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2023 to Apr 2024